Celgene Gets FDA Priority Review of Revlimid/Rituximab Combo in Lymphoma
February 26 2019 - 8:44AM
Dow Jones News
By Colin Kellaher
Celgene Corp. (CELG) on Tuesday said the U.S. Food and Drug
Administration granted priority review to its supplemental new-drug
application for Revlimid in combination with rituximab in a form of
the blood cancer lymphoma.
The Summit, N.J., biopharmaceutical company said the sNDA covers
the treatment of patients with previously treated follicular and
marginal zone lymphoma.
The FDA grants priority review to medicines that have the
potential to provide significant improvements in the treatment of a
serious disease, and the designation shortens the review
period.
Celgene, which in January announced a deal to be acquired by
Bristol-Myers Squibb Co. (BMY), said the FDA set a target action
date of June 27.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 26, 2019 08:29 ET (13:29 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Sep 2023 to Sep 2024